JP7130739B2 - 片頭痛の治療 - Google Patents

片頭痛の治療 Download PDF

Info

Publication number
JP7130739B2
JP7130739B2 JP2020519196A JP2020519196A JP7130739B2 JP 7130739 B2 JP7130739 B2 JP 7130739B2 JP 2020519196 A JP2020519196 A JP 2020519196A JP 2020519196 A JP2020519196 A JP 2020519196A JP 7130739 B2 JP7130739 B2 JP 7130739B2
Authority
JP
Japan
Prior art keywords
leucine
migraine
pharmaceutically acceptable
acetyl
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020519196A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020526575A (ja
JP2020526575A5 (enExample
Inventor
ストルップ マイケル
ファクター マロリー
Original Assignee
イントラビオ エルティーディー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59358204&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7130739(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by イントラビオ エルティーディー filed Critical イントラビオ エルティーディー
Publication of JP2020526575A publication Critical patent/JP2020526575A/ja
Publication of JP2020526575A5 publication Critical patent/JP2020526575A5/ja
Application granted granted Critical
Publication of JP7130739B2 publication Critical patent/JP7130739B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020519196A 2017-06-14 2018-06-25 片頭痛の治療 Active JP7130739B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1709459.0A GB201709459D0 (en) 2017-06-14 2017-06-14 Treatment for migraine
PCT/IB2018/054676 WO2018229738A1 (en) 2017-06-14 2018-06-25 Treatment for migraine

Publications (3)

Publication Number Publication Date
JP2020526575A JP2020526575A (ja) 2020-08-31
JP2020526575A5 JP2020526575A5 (enExample) 2021-08-12
JP7130739B2 true JP7130739B2 (ja) 2022-09-05

Family

ID=59358204

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020519196A Active JP7130739B2 (ja) 2017-06-14 2018-06-25 片頭痛の治療

Country Status (25)

Country Link
US (1) US11471434B2 (enExample)
EP (1) EP3638370B1 (enExample)
JP (1) JP7130739B2 (enExample)
KR (1) KR102594130B1 (enExample)
CN (1) CN111093772B (enExample)
AU (1) AU2018284330B2 (enExample)
CY (1) CY1123860T1 (enExample)
DK (1) DK3638370T3 (enExample)
ES (1) ES2847169T3 (enExample)
GB (1) GB201709459D0 (enExample)
HR (1) HRP20210108T1 (enExample)
HU (1) HUE053089T2 (enExample)
IL (1) IL271211B2 (enExample)
LT (1) LT3638370T (enExample)
MA (1) MA49396B1 (enExample)
MD (1) MD3638370T2 (enExample)
MX (1) MX387909B (enExample)
PL (1) PL3638370T3 (enExample)
PT (1) PT3638370T (enExample)
RS (1) RS61481B1 (enExample)
SG (1) SG11201912146RA (enExample)
SI (1) SI3638370T1 (enExample)
SM (1) SMT202100037T1 (enExample)
WO (1) WO2018229738A1 (enExample)
ZA (1) ZA201908087B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019221886B2 (en) * 2018-02-15 2024-08-08 Intrabio Ltd Therapeutic agents for treating restless legs syndrome
JP7471298B2 (ja) 2018-12-06 2024-04-19 イントラビオ エルティーディー アセチル－ロイシンの重水素化類似体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010503658A (ja) 2006-09-13 2010-02-04 ピエール、ファーブル、メディカマン アセチル−ｌ−ロイシンによるめまいの治療

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8701662L (sv) * 1987-04-22 1988-10-23 Gelder Nico M Van Saett och medel foer att behandla neurologiska sjukdomar, exempelvis migraen genom paaverkan av nervcellerna
US20040127501A1 (en) * 2002-09-24 2004-07-01 Zhengming Chen Therapeutic agents useful for treating pain
US20060063827A1 (en) 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
MY142655A (en) * 2003-06-12 2010-12-15 Euro Celtique Sa Therapeutic agents useful for treating pain
EP1641775B1 (en) * 2003-07-03 2009-02-18 Euro-Celtique S.A. 2-pyridine alkyne derivatives useful for treating pain
CN1856484B (zh) * 2003-07-24 2010-09-22 欧洲凯尔蒂克公司 用于治疗或预防疼痛的杂芳基-四氢吡啶基化合物
JP4634385B2 (ja) * 2003-09-22 2011-02-16 ユーロ−セルティーク エス．エイ． 疼痛の治療に有用なフェニル−カルボキサミド化合物
DE602004017481D1 (de) * 2003-09-22 2008-12-11 Euro Celtique Sa Zur behandlung von schmerzen geeignete therapeutische mittel
DE602004019576D1 (de) * 2003-12-30 2009-04-02 Euro Celtique Sa Zur behandlung von schmerzen geeignete piperazine
TN2010000251A1 (fr) 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
JP5876423B2 (ja) * 2010-06-22 2016-03-02 塩野義製薬株式会社 Ｔｒｐｖ１阻害活性を有する化合物とその使用
EP3103469B1 (en) 2010-06-25 2020-12-09 Shire Human Genetic Therapies, Inc. Cns delivery of therapeutic agents
ES2732818T3 (es) * 2010-11-09 2019-11-26 Mannkind Corp Composición que comprende un agonista de receptores de serotonina y una dicetopiperazina para tratar migrañas
WO2013021276A1 (en) * 2011-08-10 2013-02-14 Purdue Pharma L.P. Trpv1 antagonists including dihydroxy substituent and uses thereof
KR102791288B1 (ko) 2016-04-19 2025-04-03 인트라바이오 리미티드 이동성 및 인지 기능을 개선시키기 위한 아세틸-류신 또는 이의 약제학적으로 허용되는 염
MA43876B1 (fr) 2016-08-11 2019-04-30 Intrabio Ltd Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale
AU2017308865B2 (en) 2016-08-11 2023-04-13 Intrabio Limited Therapeutic agents for neurodegenerative diseases
LT3600276T (lt) 2017-03-28 2023-08-10 Intrabio Ltd Betahistinas arba farmaciniu požiūriu priimtina jo druska ir monoaminooksidazės inhibitorius, skirti panaudoti subjekto gydymui arba profilaktikai vieno arba daugiau vestibulinio galvos svaigimo simptomų
RU2763425C2 (ru) 2017-10-18 2021-12-29 Интрабио Лимитед Терапевтические агенты для нейродегенеративных заболеваний
WO2019079536A1 (en) 2017-10-18 2019-04-25 Intrabio Ltd THERAPEUTIC AGENTS FOR IMPROVED MOBILITY AND COGNITIVE FUNCTION AND FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES AND LYSOSOMAL STORAGE DISORDERS
AU2019221886B2 (en) 2018-02-15 2024-08-08 Intrabio Ltd Therapeutic agents for treating restless legs syndrome
JP7471298B2 (ja) 2018-12-06 2024-04-19 イントラビオ エルティーディー アセチル－ロイシンの重水素化類似体
SI3934637T1 (sl) 2019-03-02 2024-10-30 Intrabio Ltd Summit House (N-)acetil-L-levcin za uporabo pri zdravljenju travmatske poškodbe možganov
PL3989962T3 (pl) 2019-06-28 2025-11-17 Intrabio Ltd Terapia skojarzona acetyloleucyną i miglustatem w leczeniu lizosomalnej choroby spichrzeniowej
US20230051742A1 (en) 2020-01-13 2023-02-16 Intrabio Ltd. Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010503658A (ja) 2006-09-13 2010-02-04 ピエール、ファーブル、メディカマン アセチル−ｌ−ロイシンによるめまいの治療

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Equilibrium Res.，2011年，Vol.70 No.3，pp.172-175
医学のあゆみ，2015年，Vol.255 No.7，pp.757-761

Also Published As

Publication number Publication date
PL3638370T3 (pl) 2021-05-17
KR20210013518A (ko) 2021-02-04
SMT202100037T1 (it) 2021-03-15
ES2847169T3 (es) 2021-08-02
DK3638370T3 (da) 2021-01-25
US20200253905A1 (en) 2020-08-13
CN111093772A (zh) 2020-05-01
CN111093772B (zh) 2023-11-03
ZA201908087B (en) 2024-11-27
SI3638370T1 (sl) 2021-04-30
CY1123860T1 (el) 2022-05-27
WO2018229738A1 (en) 2018-12-20
AU2018284330B2 (en) 2024-03-14
IL271211B1 (en) 2023-09-01
MA49396B1 (fr) 2021-03-31
RU2020100475A (ru) 2021-07-14
KR102594130B1 (ko) 2023-10-24
CA3067321A1 (en) 2018-12-20
MD3638370T2 (ro) 2021-04-30
HRP20210108T1 (hr) 2021-03-19
EP3638370B1 (en) 2020-11-11
EP3638370A1 (en) 2020-04-22
JP2020526575A (ja) 2020-08-31
US11471434B2 (en) 2022-10-18
BR112019026660A2 (pt) 2020-07-14
MX387909B (es) 2025-03-19
MA49396A (fr) 2020-04-22
RU2020100475A3 (enExample) 2021-10-22
MX2019014784A (es) 2021-11-16
AU2018284330A1 (en) 2020-01-02
HUE053089T2 (hu) 2021-06-28
SG11201912146RA (en) 2020-01-30
PT3638370T (pt) 2021-01-26
RS61481B1 (sr) 2021-03-31
LT3638370T (lt) 2021-03-25
GB201709459D0 (en) 2017-07-26
IL271211B2 (en) 2024-01-01
IL271211A (en) 2020-01-30

Similar Documents

Publication Publication Date Title
US8309535B2 (en) Compositions and methods to treat recurrent medical conditions
KR102791288B1 (ko) 이동성 및 인지 기능을 개선시키기 위한 아세틸-류신 또는 이의 약제학적으로 허용되는 염
EP4048263A1 (en) Methods for treating neurological disorders with alpha 1a-ar partial agonists
AU748993B2 (en) Pharmaceutical combinations containing tramadol
JP7130739B2 (ja) 片頭痛の治療
KR102693607B1 (ko) 하지 불안 증후군을 치료하기 위한 치료제
RU2772278C2 (ru) Лечение мигрени
CA3067321C (en) Use of acetyle-leucine to prevent and/or treat migraine
US20140148465A1 (en) Compositions and Methods to Improve Treatment of Medical Conditions Using D-Cycloserine
WO2021231582A1 (en) Nitro-aminoadamantane compounds for the treatment of negative symptoms and cognitive impairment associated with schizophrenia
HK40023292A (en) Treatment of migraine with acetyl-leucine
HK40023292B (en) Treatment of migraine with acetyl-leucine
JP2004505919A (ja) 一次性頭痛の処置におけるビタミン配合物の使用
BR112019026660B1 (pt) Uso de acetil-leucina ou seu sal para preparação demedicamento para tratar ou prevenir enxaqueca ou sintomas associados
US20240293435A1 (en) Methods and Compositions for Treating Human Disorders Using D-Cycloserine and a Psychedelic Agent
CN1972685A (zh) 治疗复发性的需要治疗的病症的组合物及方法
HK1035143B (en) Pharmaceutical combinations containing tramadol for the production of a medicament for the treatment of migraine or migrainoid headaches

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210624

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210624

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220330

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220725

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220802

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220824

R150 Certificate of patent or registration of utility model

Ref document number: 7130739

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250